|
1
|
Caggiano V, Weiss RV, Rickert TS and
Linde-Zwirble WT: Incidence, cost and mortality of neutropenia
hospitalization associated with chemotherapy. Cancer.
103:1916–1924. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Naurois J, Novitzky-Basso I, Gill MJ,
Marti FM, Cullen MH and Roila F: ESMO Guidelines Working Group:
Management of febrile neutropenia: ESMO Clinical Practice
Guidelines. Ann Oncol. 21:(Suppl 5). v252–v256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Silber JH, Fridman M, DiPaola RS, Erder
MH, Pauly MV and Fox KR: First-cycle blood counts and subsequent
neutropenia, dose reduction, or delay in early-stage breast cancer
therapy. J Clin Oncol. 16:2392–2400. 1998.PubMed/NCBI
|
|
4
|
Klastersky J: Management of fever in
neutropenic patients with different risks of complications. Clin
Infect Dis. 39:(Suppl 1). S32–S37. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuderer NM, Dale DC, Crawford J, Cosler LE
and Lyman GH: Mortality, morbidity and cost associated with febrile
neutropenia in adult cancer patients. Cancer. 106:2258–2266. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hughes WT, Armstrong D, Bodey GP, et al:
2002 guidelines for the use of antimicrobial agents in neutropenic
patients with cancer. Clin Infect Dis. 34:730–751. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Talcott JA, Finberg R, Mayer RJ and
Goldman L: The medical course of cancer patients with fever and
neutropenia. Clinical identification of a low-risk subgroup at
presentation. Arch Intern Med. 148:2561–2568. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gala Peralta S, Cardesa Salzman T, García
García JJ, Estella Aguado J, Gené Giralt A and Luaces Cubells C:
Bacteraemia risk criteria in the paediatric febrile neutropenic
cancer patient. Clin Transl Oncol. 7:165–168. 2005.(In Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cairo MS: Dose reductions and delays:
Limitations of myelosuppressive chemotherapy. Oncology (Williston
Park). 14:(Suppl 8). 21–31. 2000.PubMed/NCBI
|
|
10
|
Bonadonna G, Moliterni A, Zambetti M,
Daidone MG, Pilotti S, Gianni L and Valagussa P: 30 years' follow
up of randomised studies of adjuvant CMF in operable breast cancer:
Cohort study. BMJ. 330:217–222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang J: Chemotherapy dose reduction and
delay in clinical practice. evaluating the risk to patient outcome
in adjuvant chemotherapy for breast cancer. Eur J Cancer. 36:(Suppl
1). S11–S14. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lyman GH, Dale DC and Crawford J:
Incidence and predictors of low dose-intensity in adjuvant breast
cancer chemotherapy: a nationwide study of community practices. J
Clin Oncol. 21:4524–4531. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lyman GH, Michels SL, Reynolds MW, Barron
R, Tomic KS and Yu J: Risk of mortality in patients with cancer who
experience febrile neutropenia. Cancer. 116:5555–5563. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
García-Carbonero R, Mayordomo JI,
Tornamira MV, et al: Granulocyte colony-stimulating factor in the
treatment of high-risk febrile neutropenia: A multicenter
randomized trial. J Natl Cancer Inst. 93:31–38. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gómez Raposo C, Pinto Marín A and González
Barón M: Colony-stimulating factors: Clinical evidence for
treatment and prophylaxis of chemotherapy-induced febrile
neutropenia. Clin Transl Oncol. 8:729–734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuderer NM, Dale DC, Crawford J and Lyman
GH: Impact of primary prophylaxis with granulocyte
colony-stimulating factor on febrile neutropenia and mortality in
adult cancer patients receiving chemotherapy: A systematic review.
J Clin Oncol. 25:3158–3167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smith TJ, Khatcheressian J, Lyman GH, et
al: 2006 update of recommendations for the use of white blood cell
growth factors: An evidence-based clinical practice guideline. J
Clin Oncol. 24:3187–3205. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aapro MS, Bohlius J, Cameron DA, et al:
European Organisation for Research and Treatment of Cancer: 2010
update of EORTC guidelines for the use of granulocyte-colony
stimulating factor to reduce the incidence of chemotherapy-induced
febrile neutropenia in adult patients with lymphoproliferative
disorders and solid tumours. Eur J Cancer. 47:8–32. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carrato A, Paz-Ares Rodríguez L, Rodríguez
Lescure A, et al: Spanish Society of Medical Oncology (SEOM):
Spanish Society of Medical Oncology consensus for the use of
haematopoietic colony-stimulating factors in cancer patients. Clin
Transl Oncol. 11:446–454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jolis L, Carabantes F, Pernas S, Cantos B,
López A, Torres P, Funes C, Caballero D, Benedit P and Salar A:
PRAXIS Study Group: Incidence of chemotherapy-induced neutropenia
and current practice of prophylaxis with granulocyte
colony-stimulating factors in cancer patients in Spain: A
prospective, observational study. Eur J Cancer Care (Engl).
22:513–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Klastersky J, Paesmans M, Rubenstein EB,
et al: The Multinational Association for Supportive Care in Cancer
risk index: A multinational scoring system for identifying low-risk
febrile neutropenic cancer patients. J Clin Oncol. 18:3038–3051.
2000.PubMed/NCBI
|
|
22
|
Lyman GH, Lyman CH and Agboola O: Risk
models for predicting chemotherapy-induced neutropenia. Oncologist.
10:427–437. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Innes H and Marshall E: Outpatient therapy
for febrile neutropenia. Curr Opin Oncol. 19:294–298.
2007.PubMed/NCBI
|
|
24
|
Flowers CR, Seidenfeld J, Bow EJ, et al:
Antimicrobial prophylaxis and outpatient management of fever and
neutropenia in adults treated for malignancy: American Society of
Clinical Oncology clinical practice guideline. J Clin Oncol.
31:794–810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lathia N, Mittmann N, DeAngelis C, Knowles
S, Cheung M, Piliotis E, Shear N and Walker S: Evaluation of direct
medical costs of hospitalization for febrile neutropenia. Cancer.
116:742–748. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saloustros E, Tryfonidis K and Georgoulias
V: Prophylactic and therapeutic strategies in chemotherapy-induced
neutropenia. Expert Opin Pharmacother. 12:851–863. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clark OA, Lyman GH, Castro AA, Clark LG
and Djulbegovic B: Colony-stimulating factors for
chemotherapy-induced febrile neutropenia: A meta-analysis of
randomized controlled trials. J Clin Oncol. 23:4198–4214. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wong GC and Tan BH: Use of antibiotics in
a haematology ward - an audit. Ann Acad Med Singapore. 37:21–26.
2008.PubMed/NCBI
|
|
29
|
Jin J, Lee YM, Ding Y, Koh LP, Lim SE, Lim
R, Tambyah PA and Hsu LY: Prospective audit of febrile neutropenia
management at a tertiary university hospital in Singapore. Ann Acad
Med Singapore. 39:453–459. 2010.PubMed/NCBI
|
